Table 1. Characteristics of 32 eligible and evaluable patients treated on study.

Median age at study entry (range)	6 Years (2–30)
Median time from diagnosis to entry (range)	12.6 Months (5.1–101)
Male : female	21: 11
Relapsed disease	16
Prior myeloablative therapy	15
Prior 131I-MIBG therapy	2
Prior irinotecan therapy	18
MYCN-amplified tumour	8/29 With data
Median Curie score at study entry (range)	11 (1–22)
Bone marrow involved at study entry	20